Used in targeted cancer therapy, particularly for acute myeloid leukemia (AML). Binds to CD33, a protein expressed on leukemic cells, enabling selective delivery of cytotoxic agents. Investigated as an antibody-drug conjugate to minimize damage to healthy cells while enhancing tumor cell death. Clinical development focused on improving remission rates in AML patients, especially those unfit for intensive chemotherapy.